A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 438 participants.

Also called NCT07477704

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 438 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT07477704
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT07477704. Randomized; no masking; primary purpose treatment. Start 2026-06-17 (actual); primary completion 2026-12-29 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
Acronym
ASCEND-QW
Condition
Hypercholesterolemia
Intervention (Drug)
Alirocumab
Lead sponsor
Regeneron Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct07477704
Content hash
52e4b860ddd5ac9da5fd74497e78cfade5f034204de6b3affc2975406834e341